• Self-Microemulsifying Delivery Boosts Luteolin Bioavailabili

  2026-05-20

  This study presents a luteolin-loaded self-microemulsifying drug delivery system (Luteolin-SME) that significantly improves oral bioavailability by inhibiting P-glycoprotein-mediated efflux. The findings have important implications for enhancing the efficacy of polyphenolic compounds with poor absorption profiles.

• Intracellular Action of Aminopeptidase Inhibitors in Myeloma

  2026-05-20

  This study uncovers that the antiproliferative effects of bestatin and actinonin in myeloma cells are mainly driven by intracellular mechanisms, rather than cell surface aminopeptidase inhibition. The research also demonstrates that drug transporters, including P-glycoprotein modulated by L-type calcium channel blockers like verapamil HCl, substantially influence intracellular inhibitor accumulation and efficacy.

• Cell Counting Kit-8 (CCK-8): Sensitive Cell Proliferation As

  2026-05-19

  Cell Counting Kit-8 (CCK-8) delivers rapid, sensitive, and reproducible quantification of cell viability and proliferation. The K1018 kit from APExBIO employs a water-soluble tetrazolium salt (WST-8) that streamlines workflows and enhances assay precision. This article details its mechanism, evidence base, and practical implementation for cancer and metabolic research.

• Chloramphenicol: Mechanistic Benchmarks in Molecular Biology

  2026-05-19

  Chloramphenicol, also known as 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide, is a potent bacterial protein synthesis inhibitor used in plasmid selection assays and antimicrobial research. Its mode of action, specificity, and high-purity availability from APExBIO make it a cornerstone antibiotic for molecular biology workflows.

• Thapsigargin: SERCA Pump Inhibitor Workflows & Optimization

  2026-05-18

  Thapsigargin empowers researchers with precise control over intracellular calcium, enabling robust endoplasmic reticulum stress and apoptosis assays. This article delivers actionable workflows, troubleshooting strategies, and expert-driven enhancements for calcium signaling and neurodegenerative disease models.

• Cell Integrity Sets Ploidy Limits in Budding Yeast Research

  2026-05-18

  This article examines how cell surface integrity restricts the maximum ploidy achievable in Saccharomyces cerevisiae, as elucidated in a recent study. The findings reveal a mechanistic link between cell membrane stress, genome duplication, and repression of ergosterol biosynthesis, with important implications for both fundamental biology and antifungal research.

• BMS 599626 Dihydrochloride: EGFR and ErbB2 Inhibitor Workflo

  2026-05-17

  BMS 599626 dihydrochloride delivers nanomolar precision for targeted EGFR and ErbB2 inhibition, optimizing cancer cell proliferation studies and tumor xenograft models. Its robust performance, validated by APExBIO and peer-reviewed research, enables reproducible workflows and actionable insights in translational oncology.

• Thiazovivin (A5506): ROCK Inhibitor Protocols in Stem Cell L

  2026-05-16

  Thiazovivin is a small molecule ROCK inhibitor that addresses cell survival and reprogramming efficiency challenges in stem cell workflows, particularly for induced pluripotent and human embryonic stem cells. It is not suitable for diagnostic or therapeutic applications, and users should adhere strictly to research-only protocols.

• Go 6983 Pan-PKC Inhibitor: Precision Tools for PKC Pathway R

  2026-05-15

  Go 6983, a potent pan-PKC inhibitor, offers nanomolar-level control over multiple protein kinase C isoforms, streamlining advanced cancer, EMT, and stem cell lineage studies. Discover how to leverage Go 6983’s selectivity in cutting-edge PKC signaling pathway research, with actionable protocols, troubleshooting insights, and lessons drawn from recent mechanistic breakthroughs.

• Dacarbazine: Mechanistic Precision and Strategy in Translati

  2026-05-15

  This thought-leadership article explores Dacarbazine’s role as an antineoplastic chemotherapy drug, dissecting its DNA alkylation mechanism, in vitro assay optimization, and translational relevance in cancers such as malignant melanoma, Hodgkin lymphoma, and sarcoma. Integrating new workflow recommendations and referencing recent advances in in vitro drug response evaluation, it offers strategic guidance for translational researchers seeking reproducibility and impact. The article contextualizes APExBIO’s Dacarbazine (SKU A2197) within the competitive reagent landscape and builds on, but distinctly extends, prior literature and product pages.

• CAPE Inhibits C. difficile TcdB and Modulates Gut Microbiota

  2026-05-14

  Guo et al. (2025) demonstrate that caffeic acid phenethyl ester (CAPE) directly inhibits the major toxin TcdB of Clostridioides difficile, reducing pathogenesis and altering gut microbiota diversity in a murine model. This study advances anti-virulence strategies for CDI by combining toxin-targeting with microbiota modulation, highlighting the potential of small molecule inhibitors beyond conventional antibiotic use.

• TH287 Enhances Radiosensitivity in Castration-Resistant Pros

  2026-05-14

  This study demonstrates that TH287, a potent MTH1 inhibitor, significantly sensitizes castration-resistant prostate cancer (CRPC) cells to ionizing radiation by promoting DNA damage and apoptosis. The work provides mechanistic insight into how precise timing of MTH1 inhibition and radiotherapy can optimize cancer cell selective cytotoxicity.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-05-13

  This study reveals that naturally occurring angiotensin peptides, including truncated forms such as Angiotensin 1/2 (2-7), significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings provide new mechanistic insight into the intersection of the renin-angiotensin system and viral pathogenesis, with important implications for blood pressure regulation and infectious disease research.

• TH287 MTH1 Inhibitor: Applied Workflows for Cancer Radiosens

  2026-05-13

  TH287, a potent MTH1 inhibitor, enables researchers to selectively induce DNA damage in cancer cells while sparing non-cancerous populations, making it a strategic tool for radiosensitization studies. This article delivers actionable protocols and troubleshooting insights, with a focus on optimizing combination regimens for castration-resistant prostate cancer.

• LY364947: Redefining TGF-β Pathway Modulation for Translatio

  2026-05-12

  This thought-leadership article explores how APExBIO’s LY364947, a selective TGF-β type I receptor kinase inhibitor, is transforming the landscape of translational research into EMT, fibrosis, and retinal degeneration. By integrating mechanistic detail, evidence-based guidance, and strategic insight, it offers a roadmap for researchers aiming to bridge preclinical findings with clinical potential.

16409 records 1/1094 page Next 12345 下5页 Last page